Response to Letter to the Editor From Malozowski: "Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial"
- PMID: 34915563
- PMCID: PMC9016423
- DOI: 10.1210/clinem/dgab879
Response to Letter to the Editor From Malozowski: "Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial"
Comment on
-
Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial.J Clin Endocrinol Metab. 2021 Oct 21;106(11):3184-3195. doi: 10.1210/clinem/dgab529. J Clin Endocrinol Metab. 2021. PMID: 34272849 Free PMC article. Clinical Trial.
-
Letter to the Editor From Malozowski: "Weekly Lonapegsomatropin in Treatment-naïve Children with Growth Hormone Deficiency: the Phase 3 heiGHt Trial".J Clin Endocrinol Metab. 2022 Apr 19;107(5):e2206-e2207. doi: 10.1210/clinem/dgab878. J Clin Endocrinol Metab. 2022. PMID: 34918085 Free PMC article. No abstract available.
References
-
- van Onzenoort HA, Menger FE, Neef C, et al. . Participation in a clinical trial enhances adherence and persistence to treatment: a retrospective cohort study. Hypertension. 2011;58(4):573-578. - PubMed
-
- Nicholas JA, Edwards NC, Edwards RA, Dellarole A, Grosso M, Phillips AL. Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis. BMC Neurol. 2020;20(1):281. doi:10.1186/s12883-020-01830-0 - DOI - PMC - PubMed